Monday, 20 November 2017

FDA approves generic Acticlate Tablets by Lupin

04 October 2017 | News

They are indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne

Source: Pixabay

Source: Pixabay

Lupin has recently announced the final approval for its Doxycycline Hyclate Tablets USP, 75 mg and 150 mg from the United States Food and Drug Administration (FDA) to market a generic version of Aqua Pharmaceuticals, LLC’s Acticlate Tablets, 75 mg and 150 mg.

Lupin’s Doxycycline Hyclate Tablets USP, 75 mg and 150 mg are the AB rated generic equivalent of Aqua Pharmaceuticals, LLC’s Acticlate Tablets, 75 mg and 150 mg.

They are indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.

Doxycycline Hyclate Tablets USP, 75 mg and 150 mg had annual sales of approximately USD 263 million in the US (IMS MAT June 2017).

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Are Indian drug firms still cautious of executing big mergers & acquistions?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls